Staphylococcal Infection
Conditions
Keywords
Methicillin-resistant Staphylococcus aureus (MRSA), cellulitis, abscess, children, elderly
Brief summary
The purpose of this clinical trial is to evaluate 2 different antibiotics, drugs that fight bacteria, \[clindamycin (CLINDA) and trimethoprim-sulfamethoxazole (TMP-SMX)\] and wound care for the outpatient management of uncomplicated skin and soft tissue infections (uSSTIs) in children and adults. The study will occur in areas where community associated methicillin-resistant Staphylococcus (S.) aureus are common. S. aureus is a type of bacteria. A total of 1310 volunteers, greater than or equal to 6 months of age and adults 85 years or younger, non-immunocompromised, with uSSTIs (in particular abscess and/or cellulitis) will be enrolled in this study. Subjects will be treated with one of the following: CLINDA, TMP-SMX, or placebo (contains no medication). Volunteers will be grouped based on the presence of cellulitis or abscess, whether the abscess can be surgically drained, and its size. The subject participation duration for this study is about 6 weeks.
Detailed description
Clinical practice in the treatment of community-onset skin and soft tissue infections (SSTI) has not kept pace with the emergence of methicillin-resistant Staphylococcus aureus (MRSA) in the community. This clinical trial will evaluate clindamycin (CLINDA) and trimethoprim-sulfamethoxazole (TMP-SMX) and wound care for the outpatient management of uncomplicated skin and soft tissue infection (uSSTI) in 3 metropolitan areas, Chicago, Los Angeles, and San Francisco, cities with high prevalence of community acquired (CA)-MRSA. This is a phase IIb multicenter, stratified, randomized, double-blind trial in which enrolled subjects with abscess or cellulitis will be treated with CLINDA, TMP-SMX, or placebo. Participants will include 1310 non-immunocompromised out-patients age 6 months to 85 years with SSTIs not requiring hospital admission. Subjects will undergo a screening/baseline evaluation, including determination of presence and size of abscess and/or presence of cellulitis. Subjects will then be randomized to receive treatment with either CLINDA, TMP-SMX, or placebo depending on whether they have: a larger drainable abscess, defined as greater than 5 cm in diameter in adults and as greater than 3 cm in diameter for ages 6-11 months, greater than 4 cm for ages 1-8 years, and greater than 5 cm for age 9 years and older; a limited drainable abscess, defined as less than or equal to 5 cm for adults and as less than or equal to 3 cm for ages 6-11 months, less than or equal to 4 cm for ages 1-8 years, and less than or equal to 5 cm for age 9 years and older; or cellulitis or erysipelas only. If the diameter of the abscess greater than 5 cm (smaller for children depending on age) or 2 or more sites of skin infection are present the subject will be randomized (1:1) to 10 days of therapy with TMP-SMX or CLINDA. If the diameter of the abscess less than or equal to 5 cm (smaller for children depending on age) then the subject will be randomized (1:1:1) to TMP-SMX, CLINDA or placebo for 10 days. Subjects with cellulitis or erysipelas only will be randomized (1:1) to TMP-SMX or CLINDA for 10 days. Subjects will be provided study drug, instructed in its use, and scheduled for 4 follow-up visits including: wound check (24-48 hours after enrollment); end of therapy (48 hours after completion of therapy); test of cure (7-10 days after completion of therapy); and a final visit at one month after completion of therapy. The primary objectives of this study are: to compare the cure rate of CLINDA to that of TMP-SMX for the treatment of patients with cellulitis or larger abscess at the Test of Cure (TOC) visit and to compare the cure rate of CLINDA, TMP-SMX, and placebo, each in conjunction with surgical drainage for the treatment of subjects with limited abscess at the TOC visit.
Interventions
DRUGTrimethoprim-sulfamethoxazole
Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
OTHERPlacebo
Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
DRUGClindamycin
CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Months to 85 Years
Healthy volunteers
No
Inclusion criteria
* Age 6 months to 85 years. * Able to complete the informed consent process or, if a minor, a parent or guardian who is able to complete the informed consent process; an assent form also will be completed for children age 7 and older. * Willing and able to complete the study protocol, study-related activities, and visits. * Diagnosis of uncomplicated skin and soft tissue infection (uSSTI), either cellulitis (defined as an inflammation of skin and associated skin structures) or abscess (defined as a circumscribed collection of pus), evidenced by at least 2 of the following localized signs or symptoms on the skin for at least 24 hours: 1. Erythema 2. Swelling or induration 3. Local warmth 4. Purulent drainage 5. Tenderness to palpation or pain * Able to take oral antibiotic therapy, either in pill or suspension form.
Exclusion criteria
* Hospital in-patient. * Hospitalization within the prior 14 days. * Residence in a long-term skilled nursing facility. * Requirement for hospitalization for skin infection or other condition. * Previous enrollment in this protocol. * Participation in another clinical trial within the previous 30 days. * Superficial skin infection only, including: 1. Impetigo 2. Ecthyma 3. Folliculitis 4. Infections that have a high cure rate after surgical incision alone (such as isolated furunculosis) or after topical or local measures * Unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete study requirements. * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with the adherence or subject compliance with study requirements. * Systolic blood pressure \> 180 mm Hg. * Systolic blood pressure (SBP) less than an age-specific critical value: 1. Age 6 - 11 months: \< 70 mm Hg 2. Age 1 to 8 years: \< 80 mm Hg 3. Age 9 to 17 years: \< 90 mm Hg 4. Age greater than or equal to 18 years: \< 90 mm Hg * Heart rate less than 45 beats per minute (BPM). * Heart rate greater than an age-specific critical value: 1. Age 6 - 11 months: \> 140 BPM 2. Age 1 to 8 years: \> 120 BPM 3. Age 9 to 17 years: \> 120 BPM 4. Age greater than or equal to 18 years: \> 120 BPM. * Oral temperature (or equivalent rectal, tympanic membrane, axillary) less than 35.5 degrees Celsius (95.9 degrees Fahrenheit). * Oral temperature (or equivalent rectal, tympanic membrane, axillary) greater than age-specific critical value: 1. Age 6 - 11 months: \> 38.0 degrees Celsius (100.4 degrees Fahrenheit) 2. Age 1 to 8 years: \> 38.5 degrees Celsius (101.3 degrees Fahrenheit) 3. Age 9 to 17 years: \> 38.5 degrees Celsius (101.3 degrees Fahrenheit) 4. Age greater than or equal to 18 years: \> 38.5 degrees Celsius (101.3 degrees Fahrenheit). * Documented human or witnessed animal bite in the past 30 days at the site of infection. * Systemic antibacterial therapy with antistaphylococcal activity within the prior 14 days. * The following concomitant medications: warfarin, phenytoin, methotrexate, rosiglitazone or sulfonylureas and systemically administered antibacterial agents with activity against staphylococci. * Diagnosed or suspected disseminated or severe Staphylococcus aureus or group A streptococcal (GAS) infection, including lymphangitic spread of skin infection, septicemia, bacteremia, pneumonia, endocarditis, osteomyelitis, septic arthritis, gangrene, necrotizing fasciitis, myositis, or other serious infections. * Infection at an anatomical skin site requiring specialized management or specialized antimicrobial therapy, including: 1. Periauricular or orbital infection 2. Perirectal infection 3. Suspected deep space infection of the hand or foot 4. Genital infection 5. Mastitis 6. Bursitis * Radiographic evidence or suspicion of gas in the tissue or foreign body infection (note: radiography is not required for screening and can be performed at the discretion of the treating physician). * Gastrointestinal symptoms such as nausea, vomiting, or diarrhea of a severity that would preclude consumption of oral antibiotics. * Hypersensitivity or history of allergic reaction to study drug. * History of glucose-6-phosphate dehydrogenase (G6PD) deficiency. * Third trimester pregnancy: pregnant women must have gestational age estimated by an objective means, e.g. ultrasound, fundal height, and women who are within 4 weeks of the third trimester of pregnancy, defined as week 27 of pregnancy, are not eligible. * Currently breast feeding. * Severe or morbid obesity with a body mass index (BMI) \>40 kg/m\^2. * Complicated skin or soft tissue infection, such as: 1. Catheter or catheter site infection within 30 days of placement 2. Surgical site infection 3. Known or suspected prosthetic device infection 4. Suspected Gram-negative or anaerobic pathogen 5. Unusual exposure history (e.g., underwater injury, fish-tank exposure, heavy soil exposure, etc) 6. Infection at the site of an area of underlying skin disease such as chronic eczema, psoriasis, atopic dermatitis, or chronic venous stasis * History of underlying immunocompromising condition or immunodeficiency, for example: 1. Diabetes mellitus 2. Chronic renal failure, creatinine clearance \<30 ml/min 3. Renal dialysis within the past 180 days 4. Human immunodeficiency virus (HIV)-positive with either cluster of differentiation (CD)4 count \<200 or \<4 percent CD4 in the past 180 days or HIV-positive and no documented CD4 count in the past 4 months 5. Organ or bone marrow transplantation (ever), immunosuppressive therapy within the past 180 days, severe liver disease 6. Other serious underlying disease, as determined by the treating physician or the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. | Test of cure (TOC) (7-10 days after completion of therapy) | Clinical failure is defined as the occurence of any of the following: 1. Lack of resolution at the Test of Cure (TOC) visit in any or all of the following: erythema, tenderness, purulent drainage, swelling, and local warmth. Erythema or tenderness that was considered due the surgical therapy itself (incision and drainage), was not considered to be indicative of clinical failure. 2. Occurrence of a SSTI at another site other than the site(s) under study. 3. Intolerance of study medication or a treatment-limiting adverse reaction necessitating discontinuation of study drug within the first 48 hours. 4. Administration of other antimicrobial therapy for treatment of a SSTI at any time through the TOC visit. 5. Unplanned surgical procedure for the infection under study at any time through the TOC visit. 6. Hospitalization for treatment of active or invasive infection at any time through the TOC visit. |
| Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population. | Test of cure (TOC) (7-10 days after completion of therapy) | Clinical failure is defined as the occurence of any of the following: 1. Lack of resolution at the Test of Cure (TOC) visit in any or all of the following: erythema, tenderness, purulent drainage, swelling, and local warmth. Erythema or tenderness that was considered due the surgical therapy itself (incision and drainage), was not considered to be indicative of clinical failure. 2. Occurrence of a SSTI at another site other than the site(s) under study. 3. Intolerance of study medication or a treatment-limiting adverse reaction necessitating discontinuation of study drug within the first 48 hours. 4. Administration of other antimicrobial therapy for treatment of a SSTI at any time through the TOC visit. 5. Unplanned surgical procedure for the infection under study at any time through the TOC visit. 6. Hospitalization for treatment of active or invasive infection at any time through the TOC visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population. | EOT visit within 48 hours of completion of therapy | Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure. |
| Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population. | EOT visit within 48 hours of completion of therapy | Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure. |
| Number of Participants Reporting Adverse Events. | End of Treatment (EOT) (48 hours after completion of therapy); Test of Cure (TOC) (7-10 days after completion of therapy); One Month Follow-up Visit (OMFU) | Subjects were issued a Memory Aid to record symptoms for 10 days post product administration. At study visits, the staff reviewed the memory aid and elicited as much information as possible about any reported symptoms. Occurrence of adverse events was solicited in the memory aid and during study visits. Reported symptoms, both solicited and unsolicited, were recorded as Adverse Events. |
| Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population. | OMFU visit | Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure, with one addition. At the OMFU, relapse (the return of the original infection after initial improvement) or recurrence (return of skin infection at original site after cure of original infection) of SSTI was scored as clinical failure. |
| Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population. | OMFU visit | Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure, with one addition. At the OMFU, relapse (the return of the original infection after initial improvement) or recurrence (return of skin infection at original site after cure of original infection) of SSTI was scored as clinical failure. |
| Number of Participants Reporting Adverse Events That Are Treatment Limiting. | End of Treatment (EOT) (48 hours after completion of therapy); Test of Cure (TOC) (7-10 days after completion of therapy); One Month Follow-up Visit (OMFU) | Participants were issued a Memory Aid to record symptoms for 10 days post product administration. At study visits, the staff reviewed the memory aid and elicited as much information as possible about any reported symptoms. Occurrence of adverse events was solicited in the memory aid and during study visits. Reported symptoms, both solicited and unsolicited, were recorded as Adverse Events. For these results, adverse events that resulted in discontinuation of study treatment for the participant were considered treatment limiting. |
Countries
United States
Participant flow
Recruitment details
Participants were non-immunocompromised out-patients age 6 months to 85 years with SSTIs not requiring hospital admission were recruited across 6 sites from communities with an anticipated prevalence of community-associated MRSA. Participants were enrolled between April 13, 2009 and January 13, 2015
Participants by arm
| Arm | Count |
|---|---|
| Cellulitis or Larger Abscess - Clindamycin Participants with cellulitis only or abscess \> 5 cm in diameter in adults and children age 9 years and older, \> 4 cm in diameter in children age 1 to 8 years, or \> 3 cm in diameter in children age 6 to 12 months, or with 2 or more sites of skin infection were treated with CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children. | 264 |
| Cellulitis or Larger Abscess - TMP-SMX Participants with cellulitis only or abscess \> 5 cm in diameter in adults and children age 9 years and older, \> 4 cm in diameter in children age 1 to 8 years, or \> 3 cm in diameter in children age 6 to 12 months, or with 2 or more sites of skin infection were treated with TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children. | 260 |
| Limited Abscess - Clindamycin Participants with limited abscess with or without cellulitis less than or equal to 5 cm in diameter in adults and children age 9 years and older, \< 4 cm in diameter in children age 1 to 8 years, or \< 3 cm in diameter in children age 6 to 12 months were treated with CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children. | 266 |
| Limited Abscess - TMP-SMX Participants with limited abscess with or without cellulitis less than or equal to 5 cm in diameter in adults and children age 9 years and older, \< 4 cm in diameter in children age 1 to 8 years, or \< 3 cm in diameter in children age 6 to 12 months were treated with TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children. | 263 |
| Limited Abscess - Placebo Participants with limited abscess with or without cellulitis less than or equal to 5 cm in diameter in adults and children age 9 years and older, \< 4 cm in diameter in children age 1 to 8 years, or \< 3 cm in diameter in children age 6 to 12 months were treated with placebo three times daily. | 257 |
| Total | 1,310 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 23 | 26 | 16 | 20 | 43 |
| Overall Study | Lost to Follow-up | 13 | 26 | 22 | 26 | 25 |
| Overall Study | Physician Decision | 3 | 3 | 2 | 3 | 2 |
| Overall Study | Protocol Violation | 6 | 1 | 1 | 2 | 0 |
| Overall Study | Randomization Error | 1 | 0 | 0 | 0 | 2 |
| Overall Study | Treatment Failure | 5 | 5 | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 9 | 5 | 4 | 5 | 9 |
Baseline characteristics
| Characteristic | Cellulitis or Larger Abscess - TMP-SMX | Limited Abscess - Clindamycin | Limited Abscess - TMP-SMX | Cellulitis or Larger Abscess - Clindamycin | Limited Abscess - Placebo | Total |
|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 74 Participants | 101 Participants | 91 Participants | 81 Participants | 89 Participants | 436 Participants |
| Age, Categorical >=65 years | 2 Participants | 1 Participants | 3 Participants | 2 Participants | 2 Participants | 10 Participants |
| Age, Categorical Between 18 and 65 years | 184 Participants | 164 Participants | 169 Participants | 181 Participants | 166 Participants | 864 Participants |
| Age, Continuous | 27.5 years STANDARD_DEVIATION 16.9 | 24.8 years STANDARD_DEVIATION 17.8 | 25.6 years STANDARD_DEVIATION 18.1 | 26.8 years STANDARD_DEVIATION 17.2 | 26.2 years STANDARD_DEVIATION 18.7 | 27.1 years STANDARD_DEVIATION 17 |
| Region of Enrollment United States | 260 participants | 266 participants | 263 participants | 264 participants | 257 participants | 1310 participants |
| Sex: Female, Male Female | 121 Participants | 126 Participants | 111 Participants | 129 Participants | 101 Participants | 588 Participants |
| Sex: Female, Male Male | 139 Participants | 140 Participants | 152 Participants | 135 Participants | 156 Participants | 722 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 59 / 264 | 72 / 260 | 61 / 266 | 52 / 263 | 60 / 257 |
| serious Total, serious adverse events | 4 / 264 | 5 / 260 | 0 / 266 | 6 / 263 | 2 / 257 |
Outcome results
Primary
Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population.
Clinical failure is defined as the occurence of any of the following: 1. Lack of resolution at the Test of Cure (TOC) visit in any or all of the following: erythema, tenderness, purulent drainage, swelling, and local warmth. Erythema or tenderness that was considered due the surgical therapy itself (incision and drainage), was not considered to be indicative of clinical failure. 2. Occurrence of a SSTI at another site other than the site(s) under study. 3. Intolerance of study medication or a treatment-limiting adverse reaction necessitating discontinuation of study drug within the first 48 hours. 4. Administration of other antimicrobial therapy for treatment of a SSTI at any time through the TOC visit. 5. Unplanned surgical procedure for the infection under study at any time through the TOC visit. 6. Hospitalization for treatment of active or invasive infection at any time through the TOC visit.
Time frame: Test of cure (TOC) (7-10 days after completion of therapy)
Population: The efficacy evaluable population was comprised of all participants who had outcomes determined at the Test of Cure (TOC) visit.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. | 89.5 percentage of participants |
| Cellulitis or Larger Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. | 88.2 percentage of participants |
| Limited Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. | 92.9 percentage of participants |
| Limited Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. | 92.7 percentage of participants |
| Limited Abscess - Placebo | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. | 80.5 percentage of participants |
Comparison: Primary null hypothesis: Clindamycin and TMP-SMX have equal rates of cure in the treatment of cellulitis/larger abscess at the Test of Cure (TOC) visit.p-value: 0.768895% CI: [-7.6, 5.1]Fisher Exact
Comparison: Primary null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess at the TOC visit.p-value: 195% CI: [-5.4, 5.1]Fisher Exact
Comparison: Primary null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess at the TOC visit.p-value: <0.000195% CI: [-19.2, -5.6]Fisher Exact
Comparison: Primary null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess at the TOC visit.p-value: 0.000295% CI: [-19.1, -5.4]Fisher Exact
Primary
Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population.
Clinical failure is defined as the occurence of any of the following: 1. Lack of resolution at the Test of Cure (TOC) visit in any or all of the following: erythema, tenderness, purulent drainage, swelling, and local warmth. Erythema or tenderness that was considered due the surgical therapy itself (incision and drainage), was not considered to be indicative of clinical failure. 2. Occurrence of a SSTI at another site other than the site(s) under study. 3. Intolerance of study medication or a treatment-limiting adverse reaction necessitating discontinuation of study drug within the first 48 hours. 4. Administration of other antimicrobial therapy for treatment of a SSTI at any time through the TOC visit. 5. Unplanned surgical procedure for the infection under study at any time through the TOC visit. 6. Hospitalization for treatment of active or invasive infection at any time through the TOC visit.
Time frame: Test of cure (TOC) (7-10 days after completion of therapy)
Population: The ITT population was comprised of all participants enrolled in the trial.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population. | 80.3 percentage of participants |
| Cellulitis or Larger Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population. | 77.7 percentage of participants |
| Limited Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population. | 83.1 percentage of participants |
| Limited Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population. | 81.7 percentage of participants |
| Limited Abscess - Placebo | Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population. | 68.9 percentage of participants |
Comparison: Primary null hypothesis: Clindamycin and TMP-SMX have equal rates of cure in the treatment of cellulitis/larger abscess at the Test of Cure (TOC) visit.p-value: 0.5295% CI: [-10.2, 4.9]Fisher Exact
Comparison: Primary null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess at the TOC visit.p-value: 0.732495% CI: [-8.4, 5.7]Fisher Exact
Comparison: Primary null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess at the TOC visit.p-value: 0.000195% CI: [-22, -6.4]Fisher Exact
Comparison: Primary null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess at the TOC visit.p-value: 0.000895% CI: [-20.8, -5]Fisher Exact
Secondary
Number of Participants Reporting Adverse Events.
Subjects were issued a Memory Aid to record symptoms for 10 days post product administration. At study visits, the staff reviewed the memory aid and elicited as much information as possible about any reported symptoms. Occurrence of adverse events was solicited in the memory aid and during study visits. Reported symptoms, both solicited and unsolicited, were recorded as Adverse Events.
Time frame: End of Treatment (EOT) (48 hours after completion of therapy); Test of Cure (TOC) (7-10 days after completion of therapy); One Month Follow-up Visit (OMFU)
Population: Participants who received treatment with either clindamycin or TMP/SMX in the cellulitis or larger abscess group and participants who received treatment with either clindamycin, TMP/SMX, or placebo in the limited abscess group.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Number of Participants Reporting Adverse Events. | 116 participants |
| Cellulitis or Larger Abscess - TMP-SMX | Number of Participants Reporting Adverse Events. | 132 participants |
| Limited Abscess - Clindamycin | Number of Participants Reporting Adverse Events. | 119 participants |
| Limited Abscess - TMP-SMX | Number of Participants Reporting Adverse Events. | 94 participants |
| Limited Abscess - Placebo | Number of Participants Reporting Adverse Events. | 119 participants |
Secondary
Number of Participants Reporting Adverse Events That Are Treatment Limiting.
Participants were issued a Memory Aid to record symptoms for 10 days post product administration. At study visits, the staff reviewed the memory aid and elicited as much information as possible about any reported symptoms. Occurrence of adverse events was solicited in the memory aid and during study visits. Reported symptoms, both solicited and unsolicited, were recorded as Adverse Events. For these results, adverse events that resulted in discontinuation of study treatment for the participant were considered treatment limiting.
Time frame: End of Treatment (EOT) (48 hours after completion of therapy); Test of Cure (TOC) (7-10 days after completion of therapy); One Month Follow-up Visit (OMFU)
Population: Participants who received treatment with either clindamycin or TMP/SMX in the cellulitis or larger abscess group and participants who received treatment with either clindamycin, TMP/SMX, or placebo in the limited abscess group.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Number of Participants Reporting Adverse Events That Are Treatment Limiting. | 1 participants |
| Cellulitis or Larger Abscess - TMP-SMX | Number of Participants Reporting Adverse Events That Are Treatment Limiting. | 0 participants |
| Limited Abscess - Clindamycin | Number of Participants Reporting Adverse Events That Are Treatment Limiting. | 6 participants |
| Limited Abscess - TMP-SMX | Number of Participants Reporting Adverse Events That Are Treatment Limiting. | 3 participants |
| Limited Abscess - Placebo | Number of Participants Reporting Adverse Events That Are Treatment Limiting. | 4 participants |
Secondary
Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population.
Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure.
Time frame: EOT visit within 48 hours of completion of therapy
Population: The efficacy evaluable population was comprised of all participants who had outcomes determined at the EOT visit.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population. | 89.2 percentage of participants |
| Cellulitis or Larger Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population. | 88.3 percentage of participants |
| Limited Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population. | 90.9 percentage of participants |
| Limited Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population. | 94.2 percentage of participants |
| Limited Abscess - Placebo | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population. | 84.9 percentage of participants |
Comparison: Null hypothesis: Clindamycin and TMP-SMX have equal rates of cure in the treatment of cellulitis/larger abscess.p-value: 0.770795% CI: [-7.1, 5.3]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.214195% CI: [-2, 8.5]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.059395% CI: [-12.4, 0.5]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.001795% CI: [-15.3, -3.1]Fisher Exact
Secondary
Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population.
Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure.
Time frame: EOT visit within 48 hours of completion of therapy
Population: All participants enrolled in the trial.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population. | 81.1 percentage of participants |
| Cellulitis or Larger Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population. | 75.4 percentage of participants |
| Limited Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population. | 78.9 percentage of participants |
| Limited Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population. | 79.8 percentage of participants |
| Limited Abscess - Placebo | Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population. | 72.4 percentage of participants |
Comparison: Null hypothesis: Clindamycin and TMP-SMX have equal rates of cure in the treatment of cellulitis/larger abscess.p-value: 0.138195% CI: [-13.1, 1.8]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.830295% CI: [-6.4, 8.2]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.083895% CI: [-14.3, 1.1]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.050795% CI: [-15.2, 0.2]Fisher Exact
Secondary
Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population.
Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure, with one addition. At the OMFU, relapse (the return of the original infection after initial improvement) or recurrence (return of skin infection at original site after cure of original infection) of SSTI was scored as clinical failure.
Time frame: OMFU visit
Population: The efficacy evaluable population was comprised of all participants who had outcomes determined at the OMFU visit.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population. | 83.9 percentage of participants |
| Cellulitis or Larger Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population. | 78.2 percentage of participants |
| Limited Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population. | 89.3 percentage of participants |
| Limited Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population. | 85.0 percentage of participants |
| Limited Abscess - Placebo | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population. | 73.9 percentage of participants |
Comparison: Null hypothesis: Clindamycin and TMP-SMX have equal rates of cure in the treatment of cellulitis/larger abscess.p-value: 0.150595% CI: [-13.3, 1.9]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.166695% CI: [-10.9, 2.2]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: <0.000195% CI: [-23, -8]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.004695% CI: [-19, -3.2]Fisher Exact
Secondary
Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population.
Measures of clinical cure and clinical failure are the same as those defined for the primary efficacy outcome measure, with one addition. At the OMFU, relapse (the return of the original infection after initial improvement) or recurrence (return of skin infection at original site after cure of original infection) of SSTI was scored as clinical failure.
Time frame: OMFU visit
Population: All participants enrolled in the trial.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cellulitis or Larger Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population. | 73.1 percentage of participants |
| Cellulitis or Larger Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population. | 67.7 percentage of participants |
| Limited Abscess - Clindamycin | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population. | 78.6 percentage of participants |
| Limited Abscess - TMP-SMX | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population. | 73.0 percentage of participants |
| Limited Abscess - Placebo | Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population. | 62.6 percentage of participants |
Comparison: Null hypothesis: Clindamycin and TMP-SMX have equal rates of cure in the treatment of cellulitis/larger abscess.p-value: 0.181595% CI: [-13.6, 2.8]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.155295% CI: [-13.2, 2.1]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: <0.000195% CI: [-24, -7.8]Fisher Exact
Comparison: Null hypothesis: After successful surgical drainage, placebo, Clindamycin, and TMP-SMX have equal rates of cure in the treatment of limited abscess.p-value: 0.014595% CI: [-18.7, -2]Fisher Exact